<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550290</url>
  </required_header>
  <id_info>
    <org_study_id>2007.07.26.E2</org_study_id>
    <nct_id>NCT00550290</nct_id>
  </id_info>
  <brief_title>Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy</brief_title>
  <official_title>Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aultman Health Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aultman Health Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized prospective study will specifically investigate the efficacy of a 24 hour
      post-operative course of broad-spectrum prophylactic antibiotics - namely Cefazolin - in
      preventing wound infection and wound breakdown following vulvectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infectious morbidity in gynecologic oncology has not been thoroughly investigated to date.
      Included in the literature are several studies that highlight substantial numbers of
      post-surgical infectious complications. Specifically among patients undergoing radical
      vulvectomy, the incidence of post-operative wound complication is as high as 58%. Surgery is
      the treatment of choice for vulvar cancer, but few studies establish protocols or management
      strategies to prevent the complications of post-operative wound infection and breakdown. This
      proposed randomized prospective study would specifically investigate the efficacy of a 24
      hour post-operative course of broad-spectrum prophylactic antibiotics - namely Cefazolin - in
      preventing wound infection and wound breakdown following vulvectomy. This same regimen has
      been described by a leader in the field of gynecology in his text - TeLinde's Operative
      Gynecology. This study will utilize two arms - one as the treatment arm utilizing 24 hours of
      prophylactic antibiotics and the other as control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Complications</measure>
    <time_frame>Two-week post-operative</time_frame>
    <description>Number of participants experiencing wound complications following vulvectomy. The presence of febrile episodes, elevated WBC counts and exam findings will be used to diagnose wound complications.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Wound Infection</condition>
  <arm_group>
    <arm_group_label>Cefazolin Preoperatively</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Cefazolin 2 grams intravenously within 30 minutes prior to incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefazolin Postoperatively</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Cefazolin 2 gram intravenous within 30 minutes prior to incision and 1 gram Cefazolin every 8 hours for the first 24 hours post-op</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin PostOperatively</intervention_name>
    <description>Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.</description>
    <arm_group_label>Cefazolin Postoperatively</arm_group_label>
    <other_name>Ancef</other_name>
    <other_name>Kefzol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin Preoperatively</intervention_name>
    <description>Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.</description>
    <arm_group_label>Cefazolin Preoperatively</arm_group_label>
    <other_name>Ancef</other_name>
    <other_name>Kefzol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All female patients 18 years of age or older undergoing surgery for vulvar carcinoma
             (this includes female patients undergoing any form of vulvectomy - radical, vulvectomy
             without groin node dissection, and partial vulvectomy)

          -  Disease State will not affect inclusion in the study. Women with previous surgery for
             vulvar carcinoma will be included as will those undergoing initial operation.

          -  Number of subjects: 160

        Exclusion Criteria:

          -  Women simultaneously undergoing treatment for other forms of cancer

          -  Women under the age of 18

          -  Pregnant patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Hopkins, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aultman Health Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William T. Schnettler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aultman Health Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aultman Health Foundation</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 25, 2007</study_first_submitted>
  <study_first_submitted_qc>October 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2007</study_first_posted>
  <results_first_submitted>January 29, 2018</results_first_submitted>
  <results_first_submitted_qc>August 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2018</results_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vulvectomy</keyword>
  <keyword>wound infection</keyword>
  <keyword>wound complication</keyword>
  <keyword>prophylactic antibiotic</keyword>
  <keyword>Post-operative wound complications following vulvectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From July, 2007 through December, 2008, all patients undergoing surgical treatment for vulvar cancer at a single tertiary care center were offered enrollment and randomization.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>24 Hour Post-operative Course of Cefazolin</title>
          <description>Patients undergoing surgical treatment for vulvar cancer randomized to an extended 24 hour post-operative course of Cefazolin</description>
        </group>
        <group group_id="P2">
          <title>Pre-operative Single Dose of Cefazolin.</title>
          <description>Patients randomized to the standard pre-operative single dosing regimen of Cefazolin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>24 Hour Post-operative Course of Cefazolin</title>
          <description>Patients undergoing surgical treatment for vulvar cancer randomized to an extended 24 hour post-operative course of Cefazolin</description>
        </group>
        <group group_id="B2">
          <title>Pre-operative Single Dose of Cefazolin.</title>
          <description>Patients randomized to the standard pre-operative single dosing regimen of Cefazolin.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wound Complications</title>
        <description>Number of participants experiencing wound complications following vulvectomy. The presence of febrile episodes, elevated WBC counts and exam findings will be used to diagnose wound complications.</description>
        <time_frame>Two-week post-operative</time_frame>
        <population>All participants who received their assigned dose of each intervention and completed all study visits were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>24 Hour Post-operative Course of Cefazolin</title>
            <description>Patients undergoing surgical treatment for vulvar cancer randomized to an extended 24 hour post-operative course of Cefazolin</description>
          </group>
          <group group_id="O2">
            <title>Pre-operative Single Dose of Cefazolin.</title>
            <description>Patients randomized to the standard pre-operative single dosing regimen of Cefazolin.</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Complications</title>
          <description>Number of participants experiencing wound complications following vulvectomy. The presence of febrile episodes, elevated WBC counts and exam findings will be used to diagnose wound complications.</description>
          <population>All participants who received their assigned dose of each intervention and completed all study visits were included in the efficacy analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>24 Hour Post-operative Course of Cefazolin</title>
          <description>Patients undergoing surgical treatment for vulvar cancer randomized to an extended 24 hour post-operative course of Cefazolin</description>
        </group>
        <group group_id="E2">
          <title>Pre-operative Single Dose of Cefazolin.</title>
          <description>Patients randomized to the standard pre-operative single dosing regimen of Cefazolin.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects recruited lead to unreliable data. A larger sample is needed to answer the research question.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jane Sewell</name_or_title>
      <organization>Aultman Health Foundation</organization>
      <phone>330-363-6793</phone>
      <email>Jane.Sewell@aultman.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

